Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study

ConclusionsIn PsA patients, efficacy responses were similar or greater with UPA15 or UPA30 versus ADA through week 104, and inhibition of radiographic progression was maintained. No new safety risks were identified with exposure to UPA through 2  years (week 104).Clinical Trial RegistrationClinicalTrials.gov, NCT03104400.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research